This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Gilead price target raised to $175 from $171 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Gilead (GILD) to $175 from $171 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
Disclaimer & DisclosureReport an Issue
- MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
- Tempus AI announce strategic collaboration with Gilead
- Kymera Therapeutics announces Gilead option exercise to license KT-200
- Gilead price target raised to $155 from $152 at Truist
- Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
